Advancing Orphan Drug Innovation And Access In Asia’s Emerging Markets
With the global orphan drug market forecasted to rise to $127 billion in the next 4 years, many expect this surge in orphan drug sales and development to be from the Asia Pacific region. With Asia’s vast population and the higher possibility of a larger number of rare disease patients here, developers are increasingly showing more interests in the area of orphan drugs in the Asia Pacific.
World Orphan Drug Congress Asia 2015 is set to bring in industry leaders and innovators from the Asia Pacific and beyond, June 3-4, 2015, at Suntec Singapore. These experts will be exploring the developmental opportunities in the rapidly growing Asian orphan drug market, as well as present successful case studies and share their vision on the future of the industry.
The annual World Orphan Drug Congress Asia 2015 is the one-stop platform for government, regulators, physicians, patient groups and industry to come together to develop sustainable market access strategies and overcome regulatory hurdles in Asia.
• Dr Vinod Mattoo, Medical Director of Cardiovascular and Metabolics at Asia Pacific, Bristol-Myers Squibb
• Ms Eisah Rahman, Senior Director of Pharmaceutical Services, Ministry of Health, Malaysia
• Ms Cynthia Loo, Executive Director Asia Pacific, BioMarin.
As a reader of Orphan Druganaut Blog, there is a 15% additional discount to attend. Just book using code “FTSK” before next Friday, 8th May. Book now
Meeting Logo courtesy of Terrapinn. The Orphan Druganaut Blog is a Media Partner.
Copyright © 2012-2015, Orphan Druganaut Blog. All rights reserved.